vaccine

The Road to a Vaccine, Ep. 1: How a COVID-19 Vaccine Might Work. Plus, How Quickly We Could Get There

Multimedia with summary

This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.

"I Have Never Seen a Moment So Rich in Collaboration, Ingenuity and Acts of Bravery": Johnson & Johnson Announces It Has Identified a Lead Covid-19 Vaccine Candidate

Chairman & CEO Alex Gorsky shares that the company could have the first batches of a Covid-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.
Blog

By Alex Gorsky, Chairman & CEO, 

The Covid-19 pandemic is one of the greatest challenges to our society in living memory.

Yet even as we are heartbroken by the lives lost and the strain on our institutions and communities, countless people have been working tirelessly to offer the world a reason to feel pride, inspiration and hope.

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Summary: 
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020
Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply
Press Release
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020
Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply

Johnson & Johnson Announces Collaboration With the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

Press Release

NEW BRUNSWICK, N.J., March 13, 2020 /3BL Media/ – Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC) to support the development of a preventive vaccine candidate for COVID-19. The parties have commenced preclinical testing of multiple vaccine prospects, with the aim to identify by the end of the month a COVID-19 vaccine candidate for clinical trials.

Alzheimer’s Disease: Why One Company Refuses to Give Up the Search for a Cure

By Jennifer Rainey Marquez
Summary: 

It's the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.

Article

It's the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.

Support for First-Line Aid to Rohingya Refugees in Bangladesh

Article

The Rohingya, a stateless Muslim minority in Myanmar, are a victim of violent repression by the Burmese army.  On October 24, 2017, the UN estimated that 604,000 Rohingya refugees have fled to Bangladesh since August 25, 2017, or about 16,000 new arrivals every day.  The vast majority of these refugees are women and children, including newborns, often fleeing the deadly violence in Rakhine State in Myanmar.

Sanofi Pasteur Receives Wellbeing Award From The Commonwealth Medical College

Award underscores company philanthropic commitments and vision
Article

Sanofi Pasteur is proud to announce it is the recipient of The Commonwealth Medical College (TCMC) Wellbeing Award. Frank Epifano, vice president, North America and global finance, commercial operations, accepted the award on October 16 at Mohegan Sun Pocono. Dr. David Greenberg, associate vice president and regional medical head, North America, and Ellyn Schindler, director, North America Corporate Social Responsibility and community engagement, accompanied Epifano.

Walter Reed Army Institute of Research to Transfer Technology

Press Release

PARIS, July 12, 2016 /3BL Media/ - Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the co-development of a Zika vaccine candidate.  According to the terms of the agreement, WRAIR will transfer its Zika purified inactivated virus (ZPIV) vaccine technology to Sanofi Pasteur, opening the door for a broader collaboration with the U.S. government.

Sanofi Pasteur to Leverage Its Strong Vaccine Legacy in Hunt for Zika Vaccine

- Building on the company's successful history in developing vaccines against similar viruses, most recently the introduction of Dengvaxia® against dengue, Sanofi Pasteur is launching a Zika vaccine project -
Press Release

LYON, France, March 10, 2016 /3BL Media/ - Sanofi Pasteur, the vaccines division of Sanofi, announced today that it has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.

Sanofi – Transport of Medicine and Environmental Preservation

Multimedia with summary

Sanofi has developed its supply chain of medicine towards a bigger environmental preservation for over 10 years.

Watch more Sanofi videos! Vist our YouTube page at SanofiTV

Pages

Subscribe to vaccine